Calmark

Calmark, together with r2 Diagnostics, has been working for a long time for a registration of Calmark Neo - Bilirubin on the Indian market. r2 Diagnostics plans to carry out a method comparison at state-accredited laboratories in the country. The result of the method comparison will be submitted to the registration authority in India as a supplement to other submitted material.

"India is an important market for Calmark, even though the registration process is complicated. We hope that this moves the process forward," comments CEO Anna Söderlund.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.